The Evolving Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia

Hematology/Oncology Clinics of North America

Volumn 27, Issue 2, 2013, Pages 355-369

  Dreger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allogeneic stem cell transplantation; Chronic lymphocytic leukemia; Minimal residual disease; Nonrelapse mortality

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLAVOPIRIDOL; FLUDARABINE; IBRUTINIB; LENALIDOMIDE; OFATUMUMAB; PROTEIN P53; PURINE DERIVATIVE; RITUXIMAB; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHROMOSOME 17P; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DONOR LYMPHOCYTE INFUSION; DRUG TREATMENT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; LEUKEMIA RELAPSE; LIFE SATISFACTION; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84875763976     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.01.007     Document Type: Review

References (56)

1. Rabinowe S.N., Soiffer R.J., Gribben J.G., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993, 82:1366-1376.
2. Khouri I.F., Keating M.J., Vriesendorp H.M., et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994, 12:748-758.
3. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
4. Michallet M., Dreger P., Sutton L., et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood 2011, 117:1516-1521.
5. Dreger P., Dohner H., McClanahan F., et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. Blood 2012, 119:4851-4859.
6. Mehta J., Powles R., Singhal S., et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996, 17:371-375.
7. Mattsson J., Uzunel M., Remberger M., et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000, 14:247-254.
8. Pavletic Z.S., Arrowsmith E.R., Bierman P.J., et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000, 25:717-722.
9. Ben Bassat I., Raanani P., Gale R.P. Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007, 39:441-446.
10. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
11. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
12. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
13. Champlin R., Khouri I., Kornblau S., et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999, 11:87-95.
14. Toze C.L., Galal A., Barnett M.J., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005, 36:825-830.
15. Farina L., Carniti C., Dodero A., et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009, 94:654-662.
16. Böttcher S., Ritgen M., Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev 2011, 25:91-96.
17. Schetelig J., van Biezen A., Brand R., et al. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective EBMT analysis. J Clin Oncol 2008, 26:5094-5100.
18. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood 2008, 111:5446-5456.
19. Moreno C., Villamor N., Esteve J., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563-4569.
20. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
21. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
22. Brown J.R., Kim H.T., Armand P., et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2012, [Epub ahead of print].
23. Pidala J., Anasetti C., Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009, 114:7-19.
24. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
25. Dreger P., Döhner H., Ritgen M., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 2010, 116:2438-2447.
26. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
27. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
28. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
29. Wierda W.G., Kipps T.J., Durig J., et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117:6450-6458.
30. Fischer K., Cramer P., Busch R., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29:3559-3566.
31. Stilgenbauer S., Zenz T., Winkler D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H trial of the GCLLSG. J Clin Oncol 2009, 27:3994-4001.
32. Lanasa M.C., Andritsos L., Brown J.R., et al. Interim analysis of EFC6663, a multicenter phase 2 study of Alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLL. ASH Annual Meeting Abstracts. Blood 2010, 116:58.
33. Badoux X.C., Keating M.J., Wen S., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
34. O'Brien S., Barrientos J., Flinn I., et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) with bendamustine/rituximab is active and tolerable in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): interim results of a phase Ib/II study. Proceedings of ASCO 2012, [abstract].
35. Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010, 28:4473-4479.
36. Gonzalez D., Martinez P., Wade R., et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011, 29:2223-2229.
37. Zenz T., Busch R., Fink A.M., et al. Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 trial of the GCLLSG. Blood (ASH Annual Meeting Abstracts) 2010, 116:2427.
38. Keating M.J., Wierda W., Tam C.S. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114:940-941. [abstract].
39. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979.
40. Bottcher S., Ritgen M., Fischer K., et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012, 30:980-988.
41. Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011, 365:2497-2506.
42. Balatti V., Bottoni A., Palamarchuk A., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012, 119:329-331.
43. Rossi D., Rasi S., Fabbri G., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012, 119:521-529.
44. Rossi D., Fangazio M., Rasi S., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012, 119:2854-2862.
45. Zenz T., Dreger P., Dietrich S., et al. Allogeneic stem cell transplantation can overcome the adverse prognostic impact of TP53 mutation in chronic lymphocytic leukemia (CLL): results from the GCLLSG CLL3x trial. Blood (ASH Annual Meeting Abstracts) 2010, 116:2357.
46. Herth I., Hegenbart U., Dietrich S., et al. First evidence that alloSCT can improve the natural course of poor-risk chronic lymphocytic leukemia (CLL) as defined by the EBMT consensus criteria: a retrospective donor vs no donor comparison. Bone Marrow Transplant 2012, 47(Suppl 1):S43-S44. [abstract].
47. Michallet M., Sobh M., Milligan D., et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 2010, 24:1725-1731.
48. Kharfan-Dabaja M.A., Pidala J., Kumar A., et al. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant 2012, 47:1164-1170.
49. Khouri I.F., Bassett R., Poindexter N., et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011, 117:4679-4688.
50. Michallet M., Sobh M., Morisset S., et al. Rituximab in allogeneic HSCT for advanced chronic lymphocytic leukemia with fludarabine + total body irradiation conditioning: results of a phase II prospective multicenter study (ITAC 02-02). Bone Marrow Transplant 2011, 46(Suppl 1):S43-S44. [abstract].
51. Badoux X.C., Keating M.J., Wang X., et al. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011, 117:3016-3024.
52. Fischer K., Cramer P., Busch R., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30:3209-3216.
53. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
54. Stilgenbauer S., Cymbalista F., Leblond V., et al. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine - interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW. Blood (ASH Annual Meeting Abstracts) 2010, 116:920.
55. Badoux X.C., Keating M.J., Wang X., et al. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 2011, 118:2085-2093.
56. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1749-1755.